Abstract
Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T-cell progenitors. We previously reported sustained calcineurin (Cn) activation in human lymphoid malignancies, and showed that Cn inhibitors have antileukemic effects in mouse models of T-ALL. It was unclear, however, from these studies whether these effects resulted from Cn inhibition in leukemic cells themselves or were an indirect consequence of impaired Cn function in the supportive tumor microenvironment. We thus generated a Notch (intracellular Notch 1, ICN1)-induced T-ALL mouse model, in which conditional Cn genetic deletion is restricted to leukemic cells. Ex vivo, Cn deletion altered the adhesive interactions between leukemic cells and their supportive stroma, leukemic cell survival, proliferation, migration and clonogenic potential. In vivo, Cn activation was found to be critical for leukemia initiating/propagating cell activity as demonstrated by the failure of Cn-deficient leukemic cells to transplant the disease to syngeneic recipient mice. Importantly, combination of vincristine treatment with Cre-mediated Cn ablation cooperated to induce long-term remission of ICN1-induced T-ALL. These findings indicate that Cn is a promising target in T-ALL relapse prevention, and call for clinical trials incorporating Cn inhibitors during consolidation therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia
Experimental Hematology & Oncology Open Access 13 November 2020
-
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer
Journal of Ovarian Research Open Access 09 August 2019
-
Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2
Nature Communications Open Access 09 November 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout







References
Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543.
Pui CH, Carroll WL, Meshinchi S, Arceci RJ . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551–565.
Aifantis I, Raetz E, Buonamici S . Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8: 380–390.
Meijerink JP . Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23: 307–318.
Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75–87.
Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269–271.
Lane SW, Scadden DT, Gilliland DG . The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150–1157.
Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932–939.
Silva A, Laranjeira AB, Martins LR, Cardoso BA, Demengeot J, Yunes JA et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res 2011; 71: 4780–4789.
Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA . Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004; 200: 659–669.
Wu H, Peisley A, Graef IA, Crabtree GR . NFAT signaling and the invention of vertebrates. Trends Cell Biol 2007; 17: 251–260.
Muller MR, NFAT Rao A . Immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010; 10: 645–656.
Neilson JR, Winslow MM, Hur EM, Crabtree GR . Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 2004; 20: 255–266.
Marafioti T, Pozzobon M, Hansmann ML, Ventura R, Pileri SA, Roberton H et al. The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas. Br J Haematol 2005; 128: 333–342.
Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ . Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005; 106: 3940–3947.
Medyouf H, Alcalde H, Berthier C, Guillemin MC, dos Santos NR, Janin A et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 2007; 13: 736–741.
Akimzhanov A, Krenacs L, Schlegel T, Klein-Hessling S, Bagdi E, Stelkovics E et al. Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling. Am J Pathol 2008; 172: 215–224.
Gachet S, Ghysdael J . Calcineurin/NFAT signaling in lymphoid malignancies. Gen Physiol Biophys 2009; 28, Spec No Focus F47–F54.
Kiani A, Rao A, Aramburu J . Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359–372.
Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res 2003; 31: e12.
Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS . Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol 2000; 20: 7505–7515.
Yashiro-Ohtani Y, He Y, Ohtani T, Jones ME, Shestova O, Xu L et al. Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes Dev 2009; 23: 1665–1676.
Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011; 473: 384–388.
Gerby B, Clappier E, Armstrong F, Deswarte C, Calvo J, Poglio S et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia 2011; 25: 1249–1258.
Suzuki J, Fujita J, Taniguchi S, Sugimoto K, Mori KJ . Characterization of murine hemopoietic-supportive (MS-1 and MS-5) and non-supportive (MS-K) cell lines. Leukemia 1992; 6: 452–458.
Winter SS, Sweatman J, Shuster JJ, Link MP, Amylon MD, Pullen J et al. Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemic cells predicts treatment outcome in children: a Pediatric Oncology Group study. Leukemia 2002; 16: 1121–1126.
Armstrong F, Brunet de la Grange P, Gerby B, Calvo J, Ballerini P, Pflumio F . NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009; 113: 1730–1740.
Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283–2291.
Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298–301.
Schmidt-Supprian M, Rajewsky K . Vagaries of conditional gene targeting. Nat Immunol 2007; 8: 665–668.
Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 2011; 118: 2849–2856.
Juarez JG, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ . CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol 2009; 145: 491–499.
Sipkins DA, Wei X, Wu JW, Runnels JM, Côté D, Means TK et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435: 969–973.
Davies C, Hogarth LA, Dietrich PA, Bachmann PS, Mackenzie KL, Hall AG et al. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. J Biol Chem 2011; 286: 37639–37650.
Rajpal A, Cho YA, Yelent B, Koza-Taylor PH, Li D, Chen E et al. Transcriptional activation of known and novel apoptotic pathways by Nur77 orphan steroid receptor. Embo J 2003; 22: 6526–6536.
Thompson J, Winoto A . During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J Exp Med 2008; 205: 1029–1036.
Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011; 208: 653–661.
Dick JE . Stem cell concepts renew cancer research. Blood 2008; 112: 4793–4807.
Ehninger A, Trumpp A . The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move. in. J Exp Med 2011; 208: 421–428.
Mercier FE, Ragu C, Scadden DT . The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol 2011; 12: 49–60.
Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H . Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. Blood 2006; 108: 305–310.
dos Santos NR, Rickman DS, de Reynies A, Cormier F, Williame M, Blanchard C et al. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 2007; 109: 3972–3981.
Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315–1321.
Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA . Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322: 1861–1865.
Acknowledgements
We thank G Crabtree for the generous gift of CnB1fl/Δ mice, W Pear for ICN1 retroviral, C da Costa for assistance in vincristine experiments, Z Maciorowski for assistance in cell sorting, F Cordelières for assistance in cell migration analyses, C Thibault and P de la Grange for assistance in transcriptomic analyses, Y Bourgeois, N Mebirouk, J Ropers for assistance with mouse husbandry, J Soulier for discussions and C Tran Quang for critical reading of the manuscript. SG was supported by predoctoral fellowships from the Ministère de l’Education Nationale et de la Recherche and Ligue Nationale Contre le Cancer; EG was supported by funds from the Agence Nationale de la Recherche (ANR) and Institut National du Cancer (INCa); DP was supported by a predoctoral fellowship from the Région Ile-de-France and Fondation ARC pour la recherche sur le cancer; MI was supported by postdoctoral fellowships from Institut Curie and Fondation pour la Recherche Médicale; CC was supported by postdoctoral fellowships from the Association for International Cancer Research (AICR) and Fondation de France; SP was supported by INCa. This work was supported by funds from the Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, CEA, Ligue Nationale Contre le Cancer (JG an FP are Equipes Labelisées la Ligue), INCa, Fondation de France, ANR and AICR.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Gachet, S., Genescà, E., Passaro, D. et al. Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia. Leukemia 27, 2289–2300 (2013). https://doi.org/10.1038/leu.2013.156
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.156
Keywords
- T-ALL
- calcineurin
- NFAT
This article is cited by
-
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia
Experimental Hematology & Oncology (2020)
-
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer
Journal of Ovarian Research (2019)
-
The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib
Leukemia (2017)
-
Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein degradation
Leukemia (2016)
-
The calcineurin/NFAT pathway is activated in diagnostic breast cancer cases and is essential to survival and metastasis of mammary cancer cells
Cell Death & Disease (2015)